APOE: A potential marker of disease progression in ALS

被引：60

作者：

Lacomblez, L

Doppler, V

Beucler, I

Costes, G

Salachas, F

Raisonnier, A

Le Forestier, N

Pradat, PF

Bruckert, E

Meininger, V

机构：

[1] Hop La Pitie Salpetriere, AH HP, Federat Neurol Mazarin, F-75013 Paris, France

[2] Hop La Pitie Salpetriere, AH HP, Serv Pharmacol, F-75013 Paris, France

[3] Hop La Pitie Salpetriere, AH HP, Serv Endocrinol, F-75013 Paris, France

[4] Hop La Pitie Salpetriere, AH HP, Lab Lipides & Lipoprot, F-75013 Paris, France

来源：

NEUROLOGY | 2002年 / 58卷 / 07期

关键词：

D O I：

10.1212/WNL.58.7.1112

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Although documented in AD, the role of APOE remains unclear in ALS. APOE phenotype and plasma levels were measured in 403 patients with ALS and were cor related with clinical parameters and survival time. No correlations were observed between the APOE phenotype, and these variables. In contrast, APOE plasma levels were correlated with both rate of deterioration and survival time and appeared to be an important risk factor for decreased survival time with a relative risk of 0.647 (95% Cl: 0.465 to 0.901; P = 0.01).

引用

页码：1112 / 1114

页数：3

共 50 条

[41] ALSFRS and appel ALS scores: Discordance with disease progression
Voustianiouk, Andrei
Seidel, Gregory
Panchal, Janki
Sivak, Mark
Czaplinski, Adam
Yen, Albert
Appel, Stanley H.
Lange, Dale J.
MUSCLE & NERVE, 2008, 37 (05) : 668 - 672
[42] Humoral factors in ALS patients during disease progression
Jared Ehrhart
Adam J. Smith
Nicole Kuzmin-Nichols
Theresa A. Zesiewicz
Israt Jahan
R. Douglas Shytle
Seol-Hee Kim
Cyndy D. Sanberg
Tuan H. Vu
Clifton L. Gooch
Paul R. Sanberg
Svitlana Garbuzova-Davis
Journal of Neuroinflammation, 12
[43] Assessing disease progression in ALS: prognostic subgroups and outliers
Alves, Ines
Gromicho, Marta
Santos, Miguel Oliveira
Pinto, Susana
de Carvalho, Mamede
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2025, 26 (1-2) : 58 - 63
[44] Effect of fluoxetine on disease progression in a mouse model of ALS
Koschnitzky, J. E.
Quinlan, K. A.
Lukas, T. J.
Kajtaz, E.
Kocevar, E. J.
Mayers, W. F.
Siddique, T.
Heckman, C. J.
JOURNAL OF NEUROPHYSIOLOGY, 2014, 111 (11) : 2164 - 2176
[45] Microglial activation in familial ALS - Contribution to disease progression?
Sargsyan, Siranush Anna
Blackburn, Daniel J.
Monk, Peter N.
Shaw, Pamela J.
NEUROLOGY, 2007, 68 (12) : A91 - A91
[46] Humoral factors in ALS patients during disease progression
Ehrhart, Jared
Smith, Adam J.
Kuzmin-Nichols, Nicole
Zesiewicz, Theresa A.
Jahan, Israt
Shytle, R. Douglas
Kim, Seol-Hee
Sanberg, Cyndy D.
Vu, Tuan H.
Gooch, Clifton L.
Sanberg, Paul R.
Garbuzova-Davis, Svitlana
JOURNAL OF NEUROINFLAMMATION, 2015, 12
[47] TNF-α/ApoE double knockout and atherosclerotic disease progression
Brånén, L
Hovgaard, L
Nitulescu, M
Nilsson, J
Jovinge, S
ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 153 - 153
[48] The association between APOE genotype and progression of Alzheimer's disease
Tsolaki, M.
Bosiki, M.
Daniilidou, M.
Pitsalidis, C. H.
Molyva, D.
Kounti, F.
Papassotiropoulos, A.
Kazis, A.
EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 58 - 58
[49] Cholesterol and APOE genotype interact to influence Alzheimer disease progression
Evans, RM
Hui, S
Perkins, A
Lahiri, DK
Poirier, J
Farlow, MR
NEUROLOGY, 2004, 62 (10) : 1869 - 1871
[50] GPR37 processing in neurodegeneration: a potential marker for Parkinson's Disease progression rate
Argerich, Josep
Garma, Leonardo D.
Lopez-Cano, Marc
Alvarez-Montoya, Paula
Gomez-Acero, Laura
Fernandez-Duenas, Victor
Munoz-Manchado, Ana B.
Aso, Ester
Boxer, Adam
Andres-Benito, Pol
Svenningsson, Per
Ciruela, Francisco
NPJ PARKINSONS DISEASE, 2024, 10 (01)

← 1 2 3 4 5 →